Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 14, 2026

Crypto Currents: SEC, CFTC sign MOU for Joint Harmonization Initiative

View original at finance.yahoo.com
Crypto Currents: SEC, CFTC sign MOU for Joint Harmonization Initiative As bitcoin, ethereum and other cryptocurrencies see major legal, institutional, and technological developments, the financial landscape continues to adapt…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 2025 was a year of consolidation and transformation for Genius Group, with operational focus on building core business of AI-powered entrepreneurial education around three business units, enabling the company to deliver lifelong learning curriculum

    60% confidence
  • Circle's volumes surpassed Tether in 2026 year-to-date for the first time since 2019

    60% confidence
  • Regulated digital asset infrastructure requires trusted institutional participants who can operate at the intersection of traditional finance and blockchain technology. Ubyx is solving a critical structural challenge by enabling multiple issuers and multiple receivers to transact seamlessly while preserving par-value integrity

    60% confidence
  • This updated Memorandum of Understanding will serve as a roadmap for a new era of harmonization between the agencies – one that is critical to support U.S. leadership in this next chapter of financial innovation

    60% confidence
  • Circle's near-term trends are promising, but the threat of lower rates over the medium-term and competition remains an overhang on the shares

    60% confidence
  • The rationale for Exodus' anticipated pivot - reducing the company's dependence on crypto market conditions - was underlined by weaker-than-expected Q4 results reflecting lower swap volumes amid declining crypto prices during the quarter

    60% confidence
  • President Trump's Truth Social post highlighting support for an open stablecoin loophole represented more saber rattling than anything else, and there is a difference between saber rattling, policy advocacy, and the trajectory of legislation

    60% confidence
  • Exodus' processed volume matched estimates and pre-announced amount, though total revenue beat estimates as take rates surprised to the upside. Price target reduced as revenue estimates are lowered in light of recent crypto volatility

    60% confidence
  • 2026 represents an important year for Hyperscale Data. The growth projected reflects expected organic expansion across AI infrastructure and digital platform operations as well as anticipated full year of contribution from Ballista

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com